
Topic
Payer Policy
Medicare, commercial payer, PBM, and formulary-policy moves that shape launch curves and gross-to-net.

Specialty· August 16, 2026 · 17 min read

Policy· August 16, 2026 · 15 min read
Ten PBMs Commit to TrumpRx Cash Prices in Real-Time Tools: The Policy Ledger
By Ran Chen#PBM#Payer Policy#Formulary Strategy

Approvals· August 10, 2026 · 14 min read
177Lu-Edotreotide (ITM-11) for GEP-NET: COMPETE Phase 3 Data and Lutathera Access
By Ran Chen#Radiolabeled Therapy#Oncology#FDA Approval

Specialty· August 10, 2026 · 19 min read
Dermatomyositis Treatment Access (2026): Brepocitinib, Octagam IVIG, and DMARDs

Specialty· August 10, 2026 · 16 min read
Rheumatoid Arthritis Treatment Access (2026): Methotrexate, Biosimilars, and JAKs

Policy· August 9, 2026 · 18 min read
340B Rebate-Model Ruling: D.C. Circuit Puts HHS in the Driver's Seat (2026)
By Ran Chen#340B#Drug Pricing#Payer Policy

Biosimilars· August 7, 2026 · 14 min read
Osteoporosis access landscape: Prolia's 10 denosumab biosimilars and Evenity
By Ran Chen#Biosimilars#Purple Book#Payer Policy

Policy· July 29, 2026 · 25 min read
FDA 503A Wellness-Peptide Vote (July 2026): Six Peptides and the Bulk-List Process

Generics· July 25, 2026 · 21 min read
FDA Green Book by the Numbers (2026): 2,882 Approved Animal Drugs, Zoetis Leads
By Ran Chen#FDA Approval#Generics#NADA

Pricing & Access· July 25, 2026 · 30 min read
NICE Appraisals by the Numbers (2026): 1,172 Appraisals, 85% Recommended
By Ran Chen#Market Access#Payer Policy#Drug Pricing